Rankings
▼
Calendar
TNGX Q1 2023 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$6M
+0.1% YoY
Gross Profit
$4M
74.7% margin
Operating Income
-$30M
-525.3% margin
Net Income
-$28M
-485.7% margin
EPS (Diluted)
$-0.29
QoQ Revenue Growth
-10.1%
Cash Flow
Operating Cash Flow
-$35M
Free Cash Flow
-$36M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$404M
Total Liabilities
$177M
Stockholders' Equity
$227M
Cash & Equivalents
$57M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$6M
$6M
+0.1%
Gross Profit
$4M
$5M
-15.3%
Operating Income
-$30M
-$25M
-19.3%
Net Income
-$28M
-$25M
-11.1%
← FY 2023
All Quarters
Q2 2023 →